Chronic Lower Back Pain Market Size, Epidemiology, In-Market Drugs Sales, Pipeline Therapies, and Regional Outlook 2025-2035

Market Overview: 

The chronic lower back pain market reached a value of USD 6.9 Billion across the top 7 markets (US, EU4, UK, and Japan) in 2024. Looking forward, IMARC Group expects the top 7 major markets to reach USD 10.5 Billion by 2035, exhibiting a growth rate (CAGR) of 3.87% during 2025-2035.

The chronic lower back pain market has been comprehensively analyzed in IMARC's new report titled "Chronic Lower Back Pain Market Size, Epidemiology, In-Market Drugs Sales, Pipeline Therapies, and Regional Outlook 2025-2035". Chronic lower back pain is a debilitating condition characterized by persistent pain in the lower back that lasts for more than 12 weeks, despite attempts to treat or manage it. The pain can be dull, achy, or sharp and is generally accompanied by stiffness, tenderness, and muscle spasms. In many cases, the pain also radiates down the legs, causing a sensation of tingling or numbness. Additionally, chronic lower back pain can limit mobility, making it difficult to perform daily activities, such as bending, lifting, sitting for long periods, etc. Diagnosing chronic lower back pain can be complex and often requires a thorough medical evaluation by a healthcare provider. The diagnostic process typically begins with a physical exam and a medical history review. Several imaging tests, including CT scans, X-rays, MRI scans, etc., may be ordered to help identify underlying structural issues like herniated discs or spinal stenosis. Numerous blood tests and diagnostic procedures may also be performed to rule out other conditions, such as infections or autoimmune disorders.

The increasing cases of muscle or ligament strain caused by heavy lifting, sudden movements, poor posture, etc., are primarily driving the chronic lower back pain market. Apart from this, the rising prevalence of several associated risk factors, such as herniated discs, spinal stenosis, sciatica, osteoporosis, degenerative disc diseases, etc., is also augmenting the market growth. Furthermore, the widespread adoption of massage therapies, including trigger point therapy and deep tissue massage, to help reduce muscle tension and promote relaxation, is creating a positive outlook for the market. Besides this, the escalating utilization of radiofrequency ablation, which involves using heat to destroy nerve fibers that transmit pain signals from the lower back to the brain, for treating the ailment is also bolstering the market growth. Moreover, numerous pharmaceutical companies are investing in R&D activities to develop analgesics or painkillers that are more effective, economically viable, and easier to administer. This, in turn, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of non-opioid pain management techniques, such as physical therapy, acupuncture, cognitive behavioral therapy, etc., for reducing pain without the risks associated with opioid use, including addiction and withdrawal symptoms, is expected to drive the chronic lower back pain market in the coming years.

IMARC Group's new report provides an exhaustive analysis of the chronic lower back pain market in the United States, EU4 (Germany, Spain, Italy, and France), the United Kingdom, and Japan. This includes treatment practices, in-market and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report, the United States has the largest patient pool for chronic lower back pain and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario, unmet medical needs, etc., have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the chronic lower back pain market in any manner.

Recent Developments:

• In March 2025, Persica Pharmaceuticals Limited announced positive topline data from its Phase 1b Modic Trial, a randomized, double-blind, placebo-controlled clinical trial assessing the safety and efficacy of PP353 as a treatment for patients with chronic low back pain associated with Modic Type 1 changes.

Key Highlights:

• Chronic lower back pain is impacting around 1.71 billion individuals globally, with a high proportion of women.
• Chronic pain appears to impact more than 20% of the European population, with a greater prevalence rate of 33-55% among patients with opioid dependence.
• The prevalence of chronic lower back pain increases with age, up to 65 years.
• It is predicted that 49-90% of persons in developed countries may experience lower back pain at some point in their lives.
• Chronic lower back pain prevalence was 4.2% in persons aged 24 to 39 years old and 19.6% in those aged 20 to 59.

Drugs:

SP-103, a 5.4% lidocaine topical system being developed by Scilex Pharmaceuticals, works by delivering a high concentration of lidocaine directly to the site of pain in the muscle tissue. This localized delivery aims to provide pain relief for chronic lower back pain by blocking nerve signals that transmit pain. SP-103 is a next-generation, triple-strength formulation of ZTlido, utilizing a nonaqueous, adhesive drug delivery system.

AMG-0103 is under clinical development by AnGes for chronic lower back pain. It is delivered via intradiscal injection. This therapeutic candidate acts by targeting NF-kB (nuclear factor kappa B), a transcription factor in patients.

LY 3857210, being developed by Eli Lilly and Company, is a P2X7 inhibitor for chronic low back pain. It works by targeting the P2X7 receptor, which plays a role in pain signaling pathways. By inhibiting this receptor, LY 3857210 aims to reduce the sensation of pain in chronic low back pain patients.

Time Period of the Study

• Base Year: 2024
• Historical Period: 2019-2024
• Market Forecast: 2025-2035

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the chronic lower back pain market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the chronic lower back pain market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current chronic lower back pain marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the chronic lower back pain market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2024 and how are they expected to perform till 2035?
• What was the country-wise size of the chronic lower back pain across the seven major markets in 2024 and what will it look like in 2024?
• What is the growth rate of the chronic lower back pain across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?

Epidemiology Insights

• What is the number of prevalent cases (2019-2035) of chronic lower back pain across the seven major markets?
• What is the number of prevalent cases (2019-2035) of chronic lower back pain by age across the seven major markets?
• What is the number of prevalent cases (2019-2035) of chronic lower back pain by gender across the seven major markets?
• What is the number of prevalent cases (2019-2035) of chronic lower back pain by type across the seven major markets?
• How many patients are diagnosed (2019-2035) with chronic lower back pain across the seven major markets?
• What is the size of the chronic lower back pain patient pool (2019-2024) across the seven major markets?
• What would be the forecasted patient pool (2025-2035) across the seven major markets?
• What are the key factors driving the epidemiological trend chronic lower back pain of?
• What will be the growth rate of patients across the seven major markets?

Chronic Lower Back Pain: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for chronic lower back pain drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the chronic lower back pain market?
• What are the key regulatory events related to the chronic lower back pain market?
• What is the structure of clinical trial landscape by status related to the chronic lower back pain market?
• What is the structure of clinical trial landscape by phase related to the chronic lower back pain market?
• What is the structure of clinical trial landscape by route of administration related to the chronic lower back pain market?